Norfolk Southern (NSC) said Monday that Brian Barr has been named chief operating officer, effective immediately, succeeding John Orr, who will transition to special board advisor to support the closing of Union Pacific (UNP) merger.
Barr has been with Norfolk Southern for two years leading the Mechanical department, the company said
Norfolk Southern shares were down 0.5% in Monday trading.
Price: $303.06, Change: $-1.86, Percent Change: -0.61%
(Corrects to reflect an enterprise value of $8.5 billion in the first paragraph.)Taylor Morrison Home (TMHC) has agreed to be acquired by Berkshire Hathaway (BRK.A, BRK.B) for $6.8 billion in cash and a total enterprise value of about $8.5 billion, the companies said Sunday.The price for the acquisition was $72.50 per share, a 24% premium to Taylor Morrison's latest closing price of $58.50 seen on May 29, the companies said.Following the anticipated H2 2026 closing of the deal, which still needs approval from Taylor Morrison stockholders and regulators, Taylor Morrison will continue to be led by its existing management team, including Chief Executive Officer Sheryl Palmer, the companies said.After closing, Taylor Morrison Home will become a private company and its shares will be delisted from the New York Stock Exchange, the companies said.Taylor Morrison shares were up nearly 24% in recent premarket activity.Price: $71.64, Change: $+13.14, Percent Change: +22.46%
Alpha Tau Medical (DRTS) said Monday that data from a pooled analysis of three prospective phase 1/2 trials of its Alpha DaRT device to treat advanced pancreatic cancer, exceeded the overall survival and safety rate compared with standard second-line chemotherapy.The oncology company said the data came from a pooled analysis of the clinical studies, which are evaluating endoscopic ultrasound-guided intratumoral Alpha DaRT treatment in patients who have locally advanced or metastatic pancreatic ductal adenocarcinoma.Alpha DaRT-treated patients who have already received two lines of chemotherapy had a median overall survival of 17.1 months in locally advanced disease, and 11.3 months in metastatic disease, the company said. This is compared with approximately nine months for and four to six months respectively for standard second-line chemotherapies, Alpha Tau Medical said.Price: $10.52, Change: $-0.31, Percent Change: -2.86%
PolyPid (PYPD) has completed its rolling new drug application submission to the US Food and Drug Administration for D-PLEX100 for the prevention of surgical site infections in patients undergoing colorectal surgery, the company said Monday.The company said it expects a potential FDA decision in Q1 2027 under the Prescription Drug User Fee Act review timeline.The submission is backed by data from a Phase 3 trial in which D-PLEX100 met its primary and all key secondary endpoints, and reduced surgical site infection risk by 60% compared with standard of care, PolyPid said.Price: $4.74, Change: $+0.02, Percent Change: +0.32%